Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Hrain biotechnology

Request full access

Hrain biotechnology is adhering to the concept of treating diseases and saving people

Huangpu, ChinaFounded 2015Biotech & Life Sciences

About Hrain biotechnology

Based in Shanghai's Zhangjiang Hi-Tech Park, Hrain Biotechnology is a biopharmaceutical firm established in 2015, concentrating on the development and production of advanced immune cell therapies for cancer. The company was founded by a team of internationally recognized scientists, with Li Guoshun serving as the legal representative and chairman. Mr. Li obtained a degree in economic management from Xiamen University in 1996.

Hrain Biotechnology's core focus is on developing tumor immunotherapy technologies to offer precise treatment solutions for cancer patients. The company’s research and development strategy centers on Chimeric Antigen Receptor T-cell (CAR-T) technology, while also advancing other platforms such as CAR-Natural Killer (CAR-NK) and T-cell receptor (TCR-T) therapies. This approach has resulted in a varied pipeline of products at different stages, from early research to mature clinical trials, targeting both hematological malignancies and solid tumors. The company's business model involves in-house research and development, conducting clinical trials in collaboration with multiple hospitals in cities like Beijing and Shanghai, and ultimately, the production and commercialization of these cell therapies.

The firm's leading technology, CAR-T cell therapy, is a gene engineering process that modifies a patient's own T cells to recognize and attack cancer cells. Another key area is CAR-NK cell therapy, which similarly engineers NK cells to target tumors. Hrain has received investigational new drug (IND) approval for several of its CAR-T products, including a treatment for advanced/metastatic renal cancer. The company has successfully raised significant capital to fund its operations, including a Series B round of $28 million and a total of over $156 million in funding from various investors like Shenzhen Capital Group, Qiming Venture Partners, and Yingke Capital.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2015
Headquarters
Huangpu, China
Employees
23
Open positions
None listed
Dealroom signal
33.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
B2C

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Apr 2021 $0 — Yingke Capital ↗
SERIES BOther financing Sep 2020 $28M $110M Spinnotec · New China Fund ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Hrain biotechnology website traffic

Latest recorded traffic for Hrain biotechnology is 1.4K monthly website visits, up 775% over the last three months. Hrain biotechnology's team declined 4.2% over the past year.

Latest monthly visits1.4K 3-month web change+775% 1-year team growth-4.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Hrain biotechnology in the Huangpu ecosystem

Live from Dealroom

The Hrain biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

Series B and later1 investor entered at this stage

  • Yingke Capital
Employees 23 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Hrain biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Hrain biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.